AB0598 Significance of non criteria anti-phospholipid antibodies in the patients with systemie lupus erythrematosus associated with antiphospholipid syndrome. (12th June 2018)

• Record Type: Journal Article
• Authors: Dryglewska, M.; Majdan, A.; Majdan, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1450
• Page End: 1451
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.7366
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which the uncontrolled activation of the immune system leads to overproduction of autoantibodies (Ab) with different mechanisms of action. Coexistence of anti-phospholipid antibodies (aPL) significantly increases the risk of thromboembolic complications and worsens the clinical course and prognosis of SLE. Objectives: The aim of study was to determine the relationship between the presence of non-criteria aPLs in SLE patients with criteria and non-criteria clinical symptoms of APS. Methods: The study involved 70 (52-female and 18-male) patients treated in the Department of Rheumatology and Connective Tissue Diseases. All patients fulfilled the SLICC classification criteria of SLE. 46/70 pts fulfilled clinical and laboratory criteria of Antiphospholipid Syndrome (I group SLE/APS-46pts) and 24/70 pts (II group SLE/aPL (+) −24) -they had criteria antibodies but did not display clinical criteria symptoms of APS. In the whole study group the mean age was: 38, 5±12, 9 years (range 18–71), the duration of the disease was 8, 3±6, 5 years (range 0–37). The presence of Ab was detected in patients' serum using the commercially available tests: aPL-immunodot assay Anti-Phospholipid 10 Dot, for the qualitative detection of IgG or IgM antibodies. Statistical data analysis was performed using Statistica v13.0 Results: In the study group of 70 patients we detected the presence of the following aPLs: a- cardiolipin IgM −33, 7%, IgG −50%; a-phosphatidic acid IgM −17, 5%, IgG −11, 2%; a-phosphatidylcholine IgM and IgG −0; a-phosphatidylethanolamine IgM and IgG −0; a-phosphatidylglycerol IgM – 4, 4%, IgG −10%; a-phosphatidylinositol IgM-11, 2%, IgG-10%; a-phosphatidylserine IgM-31, 2%, IgG-48, 7%; a-annexin V IgM −20%, IgG −10%; a-b2-GP I IgM-33, 7%, IgG-30%; a-prothrombin IgM −51, 4%, IgG-30%. The following non-criteria clinical symptoms of APS were present: nephropathy in 27, 1%, hypertension-41, 1%, livedo reticularis 11, 4%, convulsions/chorea-5, 7%, thrombocytopenia- 20% of the study group. No statistically significant differences in the frequency of occurrence of individual non-criteria aPLs, as well as non-criteria clinical symptoms of APS have been found in the examined subgroups of SLE/SAPS and SLE/aPL (+) patients. Conclusions: The prevalence of non-criteria aPLs in SLE and APS pts is similar to pts with SLE with criteria- aPL. Non-criteria clinical symptoms of APS occured with the same frequency in pts with SLE and APS and in SLE with criteria aPL. Disclosure of Interest: None declared